Apotex to Invest MXN 850 Million in Mexico, Targets Record Production in 2026

Apotex announced that it will generate an economic impact exceeding MXN 850 million in Mexico this year while reaching record production levels at its manufacturing facility in Ciudad de México. The milestone reinforces Mexico’s role as a strategic manufacturing hub within the company’s global network.

The company expects to surpass 74 million units produced at its industrial complex in the Iztacalco borough, marking the highest output since operations began in the country in 1996. The growth reflects Apotex’s integrated manufacturing model between Mexico and Canada, designed to strengthen regional supply capacity.

According to André Soresini, Vice President of Apotex Latin America, the company is approaching three decades of operations in Mexico with its strongest production performance to date, supplying medicines to patients across Mexico and nine additional Latin American markets.

Strengthening Generic Drug Production in Mexico

The finished-product facility in Mexico City is part of a broader network of nine manufacturing and distribution centers located in Canada, the United States, Mexico, and India. Globally, the company produces more than 25 billion doses annually and operates in over 70 countries.

In Mexico, Apotex offers more than 80 therapeutic options and ranks among the country’s leading generic drug manufacturers. Its production supplies both the public healthcare sector—covering treatments for diabetes, cardiovascular diseases, cancer, and central nervous system conditions—as well as private retail channels such as pharmacy chains and convenience stores.

The portfolio also includes over-the-counter products addressing common conditions such as dehydration, constipation, muscle pain, and menstrual discomfort, expanding access to essential medicines across the national market.

Employment and Skilled Workforce Integration

Apotex’s Mexican operations currently generate more than 500 direct jobs, with women representing approximately 60% of the workforce. This reflects significant female participation within the country’s pharmaceutical manufacturing sector.

The investment covering the period from April 2026 to March 2027 will further strengthen domestic production capacity for generic medicines while ensuring supply continuity for Mexico and other Latin American markets. As near-market manufacturing gains importance for regional health security, Mexico’s role as a pharmaceutical production platform continues to expand.